{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T07:50:58Z","timestamp":1791273058730,"version":"4.1.0"},"reference-count":54,"publisher":"BMJ","issue":"10","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1136\/dtb.2025.000052","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:20:22Z","timestamp":1784049622000},"page":"147-153","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Review of levodopa inhalation powder (Inbrija) for Parkinson\u2019s disease"],"prefix":"10.1136","volume":"64","clinical-trial-number":[{"clinical-trial-number":"nct02240030","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02242487","registry":"10.18810\/clinical-trials-gov"}],"member":"239","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"2026100523551528000_64.10.147.1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3233\/JPD-212851","article-title":"Mendelian Randomisation Study of Smoking, Alcohol, and Coffee Drinking in Relation to Parkinson\u2019s Disease","volume":"12","author":"Domenighetti","year":"2022","journal-title":"J Parkinsons Dis"},{"key":"2026100523551528000_64.10.147.2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(16)30230-7"},{"key":"2026100523551528000_64.10.147.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2024.107123"},{"key":"2026100523551528000_64.10.147.4","unstructured":"National Institute for Health and Care Excellence . Parkinson\u2019s disease in adults NICE guideline. 2017. Available: https:\/\/www.nice.org.uk\/guidance\/ng71 [Accessed 13 Nov 2025]."},{"key":"2026100523551528000_64.10.147.5","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S273121"},{"key":"2026100523551528000_64.10.147.6","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20161673"},{"key":"2026100523551528000_64.10.147.7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3233\/JPD-150685","article-title":"The Concept of Prodromal Parkinson\u2019s Disease","volume":"5","author":"Mahlknecht","year":"2015","journal-title":"J Parkinsons Dis"},{"key":"2026100523551528000_64.10.147.8","unstructured":"Clinical Knowledge Summaries . Parkinson\u2019s disease. 2025. Available: https:\/\/cks.nice.org.uk\/topics\/parkinsons-disease\/ [Accessed 13 Nov 2025]."},{"key":"2026100523551528000_64.10.147.9","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12237397","article-title":"REM Sleep Behavior Disorder and Cognitive Functions in Parkinson\u2019s Patients: A Systematic Review","volume":"12","author":"Marafioti","year":"2023","journal-title":"J Clin Med"},{"key":"2026100523551528000_64.10.147.10","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40265-020-01307-x","article-title":"Levodopa Inhalation Powder: A Review in Parkinson\u2019s Disease","volume":"80","author":"Paik","year":"2020","journal-title":"Drugs"},{"key":"2026100523551528000_64.10.147.11","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1097\/WNF.0000000000000540","article-title":"The Clinical Development of Levodopa Inhalation Powder","volume":"46","author":"Hauser","year":"2023","journal-title":"Clin Neuropharmacol"},{"key":"2026100523551528000_64.10.147.12","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"2026100523551528000_64.10.147.13","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.295"},{"key":"2026100523551528000_64.10.147.14","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1002\/mdc3.12476","article-title":"Differences in MDS-UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration","volume":"4","author":"Skorvanek","year":"2017","journal-title":"Mov Disord Clin Pract"},{"key":"2026100523551528000_64.10.147.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2015.10.006"},{"key":"2026100523551528000_64.10.147.16","unstructured":"National Institute for Health and Care Excellence . Parkinson\u2019s disease in adults: diagnosis and management Full guideline NICE guideline NG71. 2017. Available: https:\/\/www.nice.org.uk\/guidance\/ng71\/evidence\/full-guideline-pdf-4538466253 [Accessed 16 Nov 2025]."},{"key":"2026100523551528000_64.10.147.17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/mds.30133","article-title":"Motor Symptom Variability in Parkinson\u2019s Disease: Implications for Personalized Trial Outcomes?","volume":"40","author":"Janssen Daalen","year":"2025","journal-title":"Mov Disord"},{"key":"2026100523551528000_64.10.147.18","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26435"},{"key":"2026100523551528000_64.10.147.19","doi-asserted-by":"publisher","DOI":"10.1177\/15353702221117147"},{"key":"2026100523551528000_64.10.147.20","unstructured":"Parkinson\u2019s Foundation . Stages of Parkinson\u2019s. 2025. Available: https:\/\/www.parkinson.org\/understanding-parkinsons\/what-is-parkinsons\/stages [Accessed 25 Nov 2025]."},{"key":"2026100523551528000_64.10.147.21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s40273-021-01056-z","article-title":"Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinson\u2019s Disease: A Swedish Register-Based Study in 1823 Observations","volume":"39","author":"Norlin","year":"2021","journal-title":"Pharmacoeconomics"},{"key":"2026100523551528000_64.10.147.22","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph18189516","article-title":"Parkinson\u2019s Disease and Deep Brain Stimulation Have an Impact on My Life: A Multimodal Study on the Experiences of Patients and Family Caregivers","volume":"18","author":"Chac\u00f3n G\u00e1mez","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026100523551528000_64.10.147.23","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/mds.27862","article-title":"The movement disorder society nonmotor rating scale: Initial validation study","volume":"35","author":"Chaudhuri","year":"2020","journal-title":"Mov Disord"},{"key":"2026100523551528000_64.10.147.24","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3233\/JPD-230055","article-title":"Drugs to the Rescue: Comparison of On-Demand Therapies for OFF Symptoms in Parkinson\u2019s Disease","volume":"13","author":"Martinez-Nunez","year":"2023","journal-title":"J Parkinsons Dis"},{"key":"2026100523551528000_64.10.147.25","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12121994","article-title":"The Dashboard Vitals of Parkinson\u2019s: Not to Be Missed Yet an Unmet Need","volume":"12","author":"Chaudhuri","year":"2022","journal-title":"J Pers Med"},{"key":"2026100523551528000_64.10.147.26","unstructured":"Parkinson\u2019s UK . Drug treatments for Parkinson\u2019s. 2025. Available: https:\/\/www.parkinsons.org.uk\/sites\/default\/files\/2025-07\/10520_Drug%20Treatments%20for%20Parkinsons_92pp_V7%20%281%29.pdf [accessed 16 Nov 2025]"},{"key":"2026100523551528000_64.10.147.27","unstructured":"Joint Formulary Committee . British National Formulary: Parkinson\u2019s disease. Parkinson\u2019s disease | Treatment summaries | BNF | NICE. 2026. Available: https:\/\/bnf.nice.org.uk\/treatment-summaries\/parkinsons-disease\/ [Accessed 21 May 2026]."},{"key":"2026100523551528000_64.10.147.28","unstructured":"Eldepryl 10mg Tablets . Summary of product characteristics, 2023. Available: https:\/\/www.medicines.org.uk\/emc\/medicine\/22193\/SPC\/Eldepryl+tablets+10mg [Accessed 16 Nov 2025]."},{"key":"2026100523551528000_64.10.147.29","unstructured":"Inbrija 33mg inhalation powder, hard capsule . Summary of product characteristics. 2023. Available: https:\/\/www.medicines.org.uk\/emc\/product\/100955\/smpc [Accessed 13 Nov 2025]."},{"key":"2026100523551528000_64.10.147.30","unstructured":"Carbidopa\/Levodopa Orion 25 mg\/100 mg tablets . Summary of product characteristics. 2024. Available: https:\/\/www.medicines.org.uk\/emc\/product\/14836\/smpc [Accessed 13 Nov 2025]."},{"key":"2026100523551528000_64.10.147.31","unstructured":"Madopar 50 mg\/12.5 mg Hard Capsules . Summary of product characteristics. 2020. Available: https:\/\/www.medicines.org.uk\/emc\/product\/1110\/smpc [Accessed 13 Nov 2025]."},{"key":"2026100523551528000_64.10.147.32","unstructured":"Parkinson\u2019s UK . Wearing off and involuntary movements in parkinson\u2019s. 2022. Available: https:\/\/www.10532_Wearing off and Involuntary Movements_16pp_V3.pdf [accessed 13 Nov 2026]"},{"key":"2026100523551528000_64.10.147.33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14802\/jmd.24227","article-title":"Non-Motor Fluctuations in Parkinson\u2019s Disease: Underdiagnosed Yet Important","volume":"18","author":"Boura","year":"2025","journal-title":"J Mov Disord"},{"key":"2026100523551528000_64.10.147.34","article-title":"Implications of motor fluctuations in Parkinson\u2019s disease patients on chronic therapy (IMPACT): results from an observational registry","volume":"20","author":"Anthony","year":"2005","journal-title":"Mov Disord"},{"key":"2026100523551528000_64.10.147.35","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmab060"},{"key":"2026100523551528000_64.10.147.36","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21003"},{"key":"2026100523551528000_64.10.147.37","unstructured":"Parkinson\u2019s UK . Dyskinesia and wearing off. 2022. Available: https:\/\/www.parkinsons.org.uk\/information\/drugs\/side-effects\/dyskinesia-wearing-off [Accessed 13 Nov 2025]."},{"key":"2026100523551528000_64.10.147.38","unstructured":"Parkinson\u2019s UK . Managing wearing off and dyskinesia with Professor Richard Walker. 2025. Available: https:\/\/www.parkinson.org\/understanding-parkinsons\/movement-symptoms\/dyskinesia [Accessed 16 Nov 2025]."},{"key":"2026100523551528000_64.10.147.39","unstructured":"CADTH . CADTH COMMON DRUG REVIEW: Clinical Review Report: LEVODOPA\/CARBIDOPA (DUODOPA) (ABBVIE CORPORATION). 2018. Available: https:\/\/www.cda-amc.ca\/sites\/default\/files\/cdr\/clinical\/SR0557_DuodopaFWG_CL_Report.pdf [accessed 18 Nov 2025]"},{"key":"2026100523551528000_64.10.147.40","doi-asserted-by":"crossref","unstructured":"Hauser R , Chernick D , Formella A . Gocovri reduces disruptive motor episodes and improves function in Parkinson\u2019s disease patients with OFF episodes and dyskinesia: analysis of phase 3 trial data (1882). Neurology 2020;94.","DOI":"10.1212\/WNL.94.15_supplement.1882"},{"key":"2026100523551528000_64.10.147.41","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-019-00661-z"},{"key":"2026100523551528000_64.10.147.42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/mdc3.13593","article-title":"Intermittent Apomorphine Use for off Period Rescue in Parkinson\u2019s Disease: A Pragmatic Review of over Three Decades of Clinical Experience","volume":"10","author":"Castillo-Torres","year":"2023","journal-title":"Mov Disord Clin Pract"},{"key":"2026100523551528000_64.10.147.43","unstructured":"Medicines & Healthcare products Regulatory Agency . Inbrija (levodopa) package leaflet: information for the patient. 33 mg inhalation powder, hard capsules. 2025. Available: https:\/\/www.medicines.org.uk\/emc\/files\/pil.100955.pdf [accessed 13 Nov 2026]"},{"key":"2026100523551528000_64.10.147.44","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30405-8"},{"key":"2026100523551528000_64.10.147.45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.parkreldis.2020.10.029","article-title":"A 12-month, dose-level blinded safety and efficacy study of levodopa inhalation powder (CVT-301, Inbrija) in patients with Parkinson\u2019s disease","volume":"81","author":"Farbman","year":"2020","journal-title":"Parkinsonism Relat Disord"},{"key":"2026100523551528000_64.10.147.46","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000001143"},{"key":"2026100523551528000_64.10.147.47","unstructured":"European Medicines Agency . CHMP Assessment report: Inbrija. International non-proprietary name: levodopa. Procedure no.EMEA\/H\/C\/004786\/0000. 2019. Available: https:\/\/www.ema.europa.eu\/en\/homepage [Accessed 24 Nov 2025]."},{"key":"2026100523551528000_64.10.147.48","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/cer-2021-0178","article-title":"Indirect comparison of apomorphine sublingual film and levodopa inhalation powder for Parkinson\u2019s disease \u201cOFF\u201d episodes","volume":"11","author":"Thach","year":"2022","journal-title":"J Comp Eff Res"},{"key":"2026100523551528000_64.10.147.49","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2021.1936087"},{"key":"2026100523551528000_64.10.147.50","unstructured":"US Food and Drug Administration . NDA 209184 approval. 2018. Available: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/209184Orig1s000MedR.pdf [accessed 13 Nov 2025]"},{"key":"2026100523551528000_64.10.147.51","unstructured":"US Food and Drug Administration . Full prescribing information; INBRIJA (levodopa inhalation powder), for oral inhalation use, 2018."},{"key":"2026100523551528000_64.10.147.52","unstructured":"European Medicines Agency . Inbrija (levodopa). 2019. Available: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/inbrija [Accessed 16 Nov 2025]."},{"key":"2026100523551528000_64.10.147.53","unstructured":"National Institute for Health and Care Excellence (NICE) . Levodopa inhaled for patients with parkinson\u2019s disease who experience \u2018off\u2019 episodes (motor response fluctuations) [tsid8778]. 2025. Available: https:\/\/www.nice.org.uk\/guidance\/prioritisation\/gid-ta11728 [Accessed 21 May 2026]."},{"key":"2026100523551528000_64.10.147.54","unstructured":"European Medicines Agency . Inbrija: EPAR - Risk-management-plan summary. 2019. Available: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/marketing-authorisation\/pharmacovigilance-marketing-authorisation\/risk-management\/risk-management-plans [Accessed 16 Nov 2025]."}],"updated-by":[{"DOI":"10.1136\/dtb.2025.000052corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000}}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2025.000052","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:55:26Z","timestamp":1791269726000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2025.000052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":54,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,28]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/dtb.2025.000052"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2025.000052","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"value":"0012-6543","type":"print"},{"value":"1755-5248","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]}}}